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BACKGROUND
Cirrhosis is one of the most frequent and
severe chronic diseases worldwide. In the
initial stages it has few or no symptoms,
but advanced stages of cirrhosis are char-
acterised by reduced liver function,
complications due to portal hypertension
and neuroendocrine abnormalities with
increased activity of the sympathetic
nervous system (SNS) and renin-aldoste-
rone axis. The prognosis is severe, with an
increasing frequency of complications
including variceal bleeding, ascites and
spontaneous infections with subsequent
development of hepatic encephalopathy
and hepatorenal syndrome. More than
one-third of patients diagnosed with
cirrhosis develop oesophageal varices
within 3 years after the diagnosis is made.
Varices develop and later bleed when the
portal pressure is increased and the hepatic
vein pressure gradient (HVPG) is more
than 10e12 mm Hg. Life-threatening
spontaneous bacterial infections are
another common complication of
advanced cirrhosis. The infections are
mainly triggered by gut bacterial trans-
location, which is the migration of
microorganisms from the intestinal lumen
to the mesenteric lymph nodes or other
extraintestinal sites.1 Small intestinal
bacterial overgrowth of Gram-negative
rods, structural and functional alterations
of the intestinal mucosa and deﬁciencies
in defence mechanisms contribute to
bacterial translocation.2 Increased serum
levels of lipopolysaccharide binding
protein and circulating bacterial DNA are
markers of bacterial translocation and
both predict a poor outcome in cirrhosis
and ascites.3 4 Selective gut decontamina-
tion prevents spontaneous bacterial infec-
tions and improves survival in advanced
cirrhosis.5
Non-selective b-blockers (BB) are the
only drugs shown to improve survival in
patients with cirrhosis and medium to
large oesophageal varices.6 BB inhibit the
binding of catecholamines (norepinephrine
and epinephrine) to the b1 and
b2 adrenoreceptors. b1 blockade reduces
the cardiac output and b2 blockade
leads to splanchnic vasoconstriction. The
combined inhibition of b1 and b2 adre-
noreceptors is necessary to achieve a sufﬁ-
cient reduction in portal pressure. The
beneﬁt of BB has been attributed to portal
pressure reduction which decreases the
risk of variceal bleeding as well as other
complications of portal hypertension.7e10
There is increasing evidence to suggest
that BB also have non-haemodynamic
effects and that they may be ineffective in
early cirrhosis and may be detrimental
in certain patients with end-stage
cirrhosis.11e13 In the present paper
we propose that the beneﬁt of BB is
related both to haemodynamic and non-
haemodynamic effects during a window in
the cirrhotic disease. Outside the thera-
peutic window, BB may be ineffective or
even have detrimental effects.11e13
NON-HAEMODYNAMIC EFFECTS OF BB
Clinical evidence
To assess a possible beneﬁcial effect of BB
in cirrhosis beyond the reduced risk of
variceal bleeding, we performed a meta-
analysis of eight randomised trials with
970 patients comparing BB and isosorbide
mononitrate (IsMn) with banding ligation
for patients with oesophageal varices and
previous variceal bleeding.14 The mean
dose of BB was 48e120 mg/day and the
mean dose of IsMn was 30e60 mg/day. In
total, 98 of 480 patients randomised to BB
and IsMn and 121 of 490 patients rando-
mised to banding ligation died. Thus, BB
and IsMn reduced mortality compared
with banding ligation (RR 0.78, 95% CI
0.64 to 0.96). There were no apparent
differences between treatment groups in
the risk of upper gastrointestinal bleeding
(RR 1.15, 95% CI 0.81 to 1.63), variceal
rebleeding (RR 1.23, 95% CI 0.74 to 2.06)
or bleeding-related mortality (RR 0.75,
95% CI 0.37 to 1.50). These ﬁndings
suggest that the reduced mortality did not
reﬂect reduced bleeding rates. Additional
effects that are not related to the risk
of variceal bleeding may exist. The data
in the meta-analysis did not allow for
an assessment of the reasons for the
survival beneﬁt. However, a meta-analysis
of randomised trials and observational
studies found that BB may reduce the risk
of spontaneous bacterial peritonitis,8 an
effect that was independent of the portal
pressure response to BB.
Experimental evidence
In the early stages of cirrhosis the activity
of the SNS is close to normal levels. SNS
activity increases with the severity of
cirrhosis. In end-stage cirrhosis the SNS is
highly active. Fibres from the SNS termi-
nate in blood vessels, gut-associated
lymphatic tissue and the intestinal
mucosa. The level of norepinephrine
increases with the activity of the SNS. In
the intestinal lumen, norepinephrine is
absorbed by gut bacteria resulting in an
increased growth of Escherichia coli and
other Gram-negative bacteria.15 16 The
absorption also increases the bacterial
virulence and ability to adhere to the gut
mucosa.15 16 The increased norepinephrine
levels are also known to decrease the
intestinal transit time, impair the mucosal
barrier function and inhibit chemotaxis
and phagocytosis.17 In experimental
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cirrhosis, splanchnic sympathectomy
and BB reduce the rate of spontaneous
bacterial translocation and migration of
E coli to the peritoneal cavity and the
bloodstream.18 19
THE THERAPEUTIC WINDOW OF BB
We hypothesise that BB improve survival
in cirrhosis during a certain window in the
disease (ﬁgure 1).
When does the window open?
BB have no clear effects in early cirrhosis
without varices or ascites.13 At this stage
of cirrhosis the portal pressure is increased
but has not reached the threshold value of
10 mm Hg. The SNS is not substantially
activated and the splanchnic blood ﬂow is
normal. Clinical trials have not found
beneﬁcial effects of BB on clinical end-
points (ie, complications of portal hyper-
tension or death) in this patient group.13
Indeed, BB fail to reduce portal pressure in
patients with an HVPG <10 mm Hg.20
As the portal pressure increases the SNS
becomes increasingly activated and gut
bacterial translocation and splanchnic
hyperaemia occur.21 Medium to large
oesophageal varices and ascites develop.
The current treatment recommendations
specify that BB should not be used before
medium to large oesophageal varices are
developed. The experimental evidence
suggests that the non-haemodynamic
effects begin when gut bacterial trans-
location is seen at the stage of decom-
pensated cirrhosis with ascites.
Pathological gut bacterial translocation
does not occur in experimental cirrhosis
until ascites appears.19 22 In observational
studies, bacterial translocation is seen
in patients with advanced (Child C)
cirrhosis but not in those with earlier
stages of the disease (Child AeB).23
The exact time when the therapeutic
window opens may be debated. The
question may be answered in an ongoing
multicentre randomised controlled trial
(NCT01059396) which is being conducted
to assess whether BB decrease the risk
of decompensation in patients with
compensated cirrhosis and portal hyper-
tension with an HVPG >10 mm Hg.
When does the window close?
End-stage cirrhosis is associated with
pronounced circulatory changes and high
SNS activity. Both aspects may inﬂuence
the upper limit of the therapeutic window.
< In end-stage cirrhosis the circulatory
changes are related to the cardiac
output, which is increased to preserve
blood pressure and organ perfusion due
to the peripheral vasodilation. The
result is a gradual decrease in the
cardiac compensatory reserve. Mainte-
nance of an increased cardiac output
improves survival.24 25 Conversely,
a fall in the cardiac output is associated
with the development of hepatorenal
syndrome and has a negative impact on
survival.24 26 BB are cardio-inhibitory
and reduce the cardiac output and the
cardiac compensatory reserve.
< Patients with refractory ascites have
increased levels of proinﬂammatory
cytokines in the splanchnic compart-
ment. Chronic inﬂammation may
induce a b to a adrenergic shift with
a reduced expression of b-adrenergic
receptors and loss of sympathetic nerve
ﬁbres.27 The effects of BB are thereby
diminished.
The combined evidence suggests that
the beneﬁcial effects of BB are lost in end-
stage cirrhosis (ﬁgure 1). In theory, BB
may have detrimental effects in end-stage
cirrhosis due to their negative effect on
the cardiac compensatory reserve. An
observational study found that BB may
decrease survival in advanced cirrhosis
with refractory ascites.11 The patients in
the study were not randomised to receive
BB. Confounding by indication may
inﬂuence the overall results. Since the
choice to treat the included patients with
BB may reﬂect underlying prognostic
factors (known and unknown), the
evidence does not allow for clear treat-
ment recommendations. However, we
believe that high doses of BB need to be
used with great care or perhaps avoided in
patients with refractory ascites.
SUGGESTIONS FOR FUTURE RESEARCH
Additional evidence is needed to deter-
mine the non-haemodynamic effects of BB
and the therapeutic window for them.
However, performing trials or studies to
test these questions is very difﬁcult. At
present we have no reliable methods to
test the effects of BB on the SNS activity
in the splanchnic compartment. The
plasma concentrations of norepinephrine
are unreliable because they depend on
the release rate and clearance from the
plasma pool and because post-synaptic
concentrations may be up to 1000 times
higher than plasma levels. In theory,
the non-haemodynamic effects of BB may
be identiﬁed in large multicentre multi-
national randomised controlled trials
comparing BB with placebo. One potential
outcome measure could be spontaneous
bacterial peritonitis, which is a clinical
marker of gut bacterial translocation.
The trial would have to include patients
with ascites but exclude those with
medium to large varices for ethical
reasons. Considering that several patients
have contraindications to BB or decline
participation, the number of patients to be
screened would be considerable. Alterna-
tively, it would be possible to use surro-
gate markers of bacterial translocation
such as increased serum lipopolysaccha-
ride binding protein or circulating frag-
ments of bacterial DNA as outcome
measures.3 4Figure 1 Hypothesis of the therapeutic window for non-selective b-blockers (BB) in cirrhosis.
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Conventional echocardiography is not
useful for assessing the cardiac compensa-
tory reserve. First, it is dependent on age
and the preload and afterload condition.
Second, systolic dysfunction or impaired
reserve is subclinical at rest and will only be
clinically signiﬁcant with increasing circu-
latory demands as seen during acute
complications. This takes a cardiac stress
test to unmask. This has not been studied
prospectively in advanced cirrhosis and cut-
off values cannot be recommended. Cardiac
output in advanced cirrhosis may be
inﬂuenced intrinsically due to reduced
contractility or impaired chronotropic
responses, but it is also highly dependent
on the preload and afterload condition.
Potential options include a dobutamine test
or an afterload test with a loading inde-
pendent echocardiography measure or MRI
to assess the rise or fall in left ventricular
ejection fraction, respectively.28e31 Tread-
mill testing is difﬁcult in patients with
advanced cirrhosis as they are often in poor
shape, have muscle wasting and may also
have pulmonary dysfunction.
Current evidence supports the notion
that BB act in cirrhosis through haemo-
dynamic and non-haemodynamic mecha-
nisms in a window period of cirrhosis. The
non-haemodynamic effects of BB may
improve survival in a proportion of
patients with cirrhosis and ascites with
repeated gut bacterial translocation and
no (or small) oesophageal varices. These
patients are not offered BB today. Addi-
tional clinical and experimental research is
needed to analyse the effects of BB in
different stages of the disease and
to identify valid surrogate markers for
clinical outcome measures.
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